Boost yield, purity and patient safety with GMP-compliant enzymes
In biopharma manufacturing processes like viral vector and vaccine production, residual host-cell DNA doesn’t just float free – it’s bound in chromatin, tightly complexed with proteins and therapeutic product. Conventional nucleases lose power in these conditions, leaving DNA fragments behind.
SAN HQ & M-SAN HQ – ArcticZymes’ original salt-active nucleases are engineered to work where others fail. Reliable at physiological or high-salt conditions, they're GMP-compliant and backed by 30+ years of expertise and ISO 13485 certification.
Why choose SAN HQ & M-SAN HQ
- Unrivaled chromatin digestion leads to measurable gains across yield, process efficiency, cost and product quality
- Simplifies downstream processing by eliminating additional nuclease steps and reducing chromatography and filtration complexity
- Proven, large-scale economic impact
- 70% lower nuclease cost per batch and >40% lower cost per dose
- Significant operational efficiency gains
- Up to 4× less nuclease needed, 70% faster processing, and 10× better host cell DNA clearance
From discovery to GMP scale, SAN HQ & M-SAN HQ enable faster, cleaner and more compliant manufacturing.
Tell us about your process needs and our experts will guide you to the right solution. Just fill out the form on this page and a member from our Pharma team will be in touch.
A new look at viral vector manufacturing economics
What is really driving your cost per dose?
A new whitepaper from ArcticZymes explores a hidden bottleneck in downstream processing and the impact of an optimized nuclease strategy. The analysis shows how this approach can improve recovery and reduce cost across your process.